Analyzing True Drinks (TRUU) & Canopy Growth (CGC)

13.5% of Canopy Growth shares are held by institutional investors. 18.2% of True Drinks shares are held by company insiders. Strong institutional …

Canopy Growth (NYSE:CGC) and True Drinks (OTCMKTS:TRUU) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Institutional & Insider Ownership

13.5% of Canopy Growth shares are held by institutional investors. 18.2% of True Drinks shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Canopy Growth and True Drinks’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Canopy Growth $60.79 million 178.58 -$54.88 million ($0.32) -146.13
True Drinks $3.82 million 0.17 -$12.44 million N/A N/A

True Drinks has lower revenue, but higher earnings than Canopy Growth.

Volatility & Risk

Canopy Growth has a beta of 4.46, suggesting that its stock price is 346% more volatile than the S&P 500. Comparatively, True Drinks has a beta of 4.75, suggesting that its stock price is 375% more volatile than the S&P 500.


This table compares Canopy Growth and True Drinks’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Canopy Growth -267.40% -14.39% -11.12%
True Drinks N/A N/A -236.18%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Canopy Growth and True Drinks, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Canopy Growth 0 4 4 0 2.50
True Drinks 0 0 0 0 N/A

Canopy Growth currently has a consensus price target of $55.76, indicating a potential upside of 19.24%. Given Canopy Growth’s higher possible upside, equities research analysts plainly believe Canopy Growth is more favorable than True Drinks.


Canopy Growth beats True Drinks on 6 of the 11 factors compared between the two stocks.

About Canopy Growth

Canopy Growth logoCanopy Growth Corp. engages in the production and sale of medical cannabis. The company offers products including oils and concentrates, soft gel capsules, and hemp. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.

About True Drinks

True Drinks logoTrue Drinks Holdings, Inc. develops, markets, sells, and distributes naturally flavored water in the United States. The company offers AquaBall Naturally Flavored Water, a zero-sugar, zero-calorie, preservative-free, vitamin-enhanced, and naturally flavored water drink. It also markets and distributes Bazi All Natural Energy, a liquid nutritional supplement drink. True Drinks Holdings, Inc. distributes its products through various retail channels, such as grocery and convenience stores, mass merchandisers, and drug stores, as well as through its e-commerce platform. The company was formerly known as True Drinks, Inc. and changed its name to True Drinks Holdings, Inc. in October 2012. True Drinks Holdings, Inc. was founded in 2008 and is headquartered in Irvine, California.

Receive News & Ratings for Canopy Growth Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Canopy Growth and related companies with’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

DNAnexus launches innovative clinico-genomic cohort browser to accelerate research and discovery

DNAnexus, Inc., the leader in biomedical informatics and data management, today announced the addition of an innovative browser for …
Mar 12 2019

DNAnexus, Inc., the leader in biomedical informatics and data management, today announced the addition of an innovative browser for clinico-genomic cohorts to its DNAnexus Apollo Platform, allowing for easy at-scale navigation and exploration on combined genotypic and phenotypic data. The DNAnexus Platform has been used by scientists at the Regeneron Genetics Center (RGC) as part of its effort to sequence, analyze, and deliver the exome data of the UK Biobank (UKB) study. Starting today, the UKB is releasing a data set of 50,000 exomes and combined phenotypes to the greater research community. Researchers with approved access can upload their UKB data to DNAnexus Apollo and use the cohort browser to accelerate research and discovery.

DNAnexus Apollo is an enhanced platform for data science exploration, analysis, and discovery, designed to empower R&D teams globally. The addition of the cohort browser allows diverse teams the ability to rapidly ask questions of data through a powerful yet intuitive user interface. Biologists and bioinformaticians alike can quickly and easily navigate and filter any number of phenotypic fields and genetic variants for population-scale data exploration and insight discovery.

The RGC, in collaboration with several pharmaceutical companies, has undertaken the exome sequencing and analysis of the UK Biobank study, a biospecimen collection from more than 500,000 individuals. The center uses DNAnexus to run bioinformatics pipelines and deliver the results back to collaborators. As part of this delivery, the RGC successfully deployed the cohort browser on a collection of thousands of phenotypic fields extracted from the UK Biobank and millions of genetic variants computed through its scientific pipelines.

There is a tremendous amount of knowledge waiting to be gleaned from the UK Biobank collection, and DNAnexus has been a key partner in helping us navigate the complexities of generating and delivering this data to the UK Biobank and our pharma partners in the exome sequencing project.”

Jeffrey Reid, Vice President and Head of Genome Informatics & Data Engineering at Regeneron Pharmaceuticals

Scientists can bring their data to DNAnexus Apollo and use our cohort browser for easy and rapid exploration, querying potentially thousands of phenotype fields and millions of genetic variants in a matter of seconds. Once all UK Biobank participants become sequenced and the data publicly available, the underlying data matrix will consist of trillions of data points, and our technology has been designed to handle this extreme scale. DNAnexus has long been at the forefront of scalable informatics and we are pleased to offer this novel solution to the research community.”

Richard Daly, Chief Executive Officer of DNAnexus

A DNAnexus talk titled Illuminating the Path Towards Precision Medicine with DNAnexus Apollo and UK Biobank will take place during Molecular Med Tri-Con Conference on Tuesday, March 12th at 3:10 p.m. at Moscone South Convention Center, room 151.

Related Posts:

  • No Related Posts

Tiburio Therapeutics Inc. Appoints Nerissa Kreher, MD, Chief Medical Officer

The company was launched out of orphan drug accelerator Cydan with financing from leading life sciences investors, New Enterprise Associates, …

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar 12, 2019–Tiburio Therapeutics Inc. (Tiburio), a private biopharmaceutical company focused on developing treatments for rare neuroendocrine tumors and endocrine diseases, today announced the appointment of Nerissa Kreher, MD, to the newly created position of Chief Medical Officer. Dr. Kreher brings 13 years of experience in medical affairs and clinical development from leading biotechnology companies, most recently serving as Chief Medical Officer at AVROBIO, a gene therapy company. There, she led all clinical development and clinical operations for multiple global rare disease programs, including programs for Fabry and Gaucher disease, among others.

This press release features multimedia. View the full release here:

Nerissa Kreher, MD, Chief Medical Officer (Photo: Business Wire)

“We are very fortunate to have Nerissa join Tiburio given her clinical expertise in endocrinology and breadth of experience leading the advancement of clinical-stage programs for rare diseases at some of the most recognized companies in the industry,” said Abraham N. Ceesay, Chief Executive Officer of Tiburio. “Throughout her career, she has shown tremendous dedication to the rare disease communities she’s served. We look forward to her leadership and expertise progressing our lead program with TBR-760 into a Phase 2 clinical trial for patients with non-functioning pituitary adenoma in the second half of 2019.”

Nerissa brings deep academic, clinical research and biotechnology industry experience and she has held leadership roles in both clinical development and medical affairs at large, public and private, start-up biotechnology companies. Prior to AVROBIO, Dr. Kreher was the Global Head of Clinical and Medical Affairs at Zafgen, a clinical-stage biopharmaceutical company developing therapies for the treatment of metabolic diseases. In the role, she led the clinical team responsible for advancing the development of their lead program for Prader-Willi syndrome. Previously, she was Global Clinical Development Lead for Shire HGT and Executive Medical Director of Metabolic Disorders at Alexion Pharmaceuticals. Dr. Kreher began her career as Director, Medical Affairs at Serono and Medical Director at Genzyme. She received her M.D. from East Carolina University, her B.S. in biology from University of North Carolina at Chapel Hill and an M.S. in clinical research from Indiana University-Purdue University Indianapolis. Dr. Kreher holds an executive MBA from Northeastern University Graduate School of Business Administration.

“The chasm between patients diagnosed with a rare disease and the treatments available for them is vast and this is especially true for the rare neuroendocrine diseases Tiburio is tackling. In an effort to bridge that gap, I’ve spent my career helping companies bring new potential therapies to largely underserved patient populations and look forward to doing the same at Tiburio,” said Nerissa Kreher, MD, Chief Medical Officer of Tiburio. “I’m thrilled to join the team and help the company advance what we hope will be the first non-invasive and effective treatment for patients suffering from these debilitating and life-altering pituitary tumors.”

About Tiburio

Tiburio is a clinical stage biopharmaceutical company dedicated to advancing novel treatments for rare neuroendocrine tumors and rare endocrine diseases where there is significant patient need. Our pipeline consists of two clinical stage compounds, TBR-760 for the treatment of non-functioning pituitary adenoma (NFPA), and TBR-065 for additional rare endocrine diseases. The company was launched out of orphan drug accelerator Cydan with financing from leading life sciences investors, New Enterprise Associates, Longitude Capital, Lundbeckfonden Ventures, and Alexandria Venture Investments. Tiburio is located in Technology Square in Cambridge, Mass. For more information, please visit

View source version on

CONTACT: Media Contact:

Courtney Heath

Scient Public Relations, Inc.

(617) 872-2462



SOURCE: Tiburio Therapeutics Inc.

Copyright Business Wire 2019.

PUB: 03/12/2019 08:00 AM/DISC: 03/12/2019 08:01 AM

Renowned geneticist keynotes OU genomics symposium

The event also reaffirmed OU’s multi-year commitment to expand research and training in the field of genomics and big data analytics, and provided a …

The Oakland University Department of Biological Sciences recently hosted a genomics symposium, drawing researchers from around the country to discuss the latest advances in a field that is providing new insights into the function of genes, the promise of genomic medicine and the history of life itself.

The event was keynoted by Dr. Stephen J. O’Brien, one of the world’s preeminent researchers in genomic science. The professor from Nova Southeastern University spoke about his groundbreaking discoveries, and highlighted many ways that genomics research is contributing to the health and welfare of humans and animals.

Stephen J. O'Brien

Dr. Stephen O’Brien spoke about the past, present and future of genomics research.

Dr. O’Brien is widely recognized for discovering the first AIDS restriction gene, which helped save thousands of lives. He is also known for his 25-year tenure as Chief of the Laboratory of Genomics Diversity at the National Cancer Institute, and as founder of the Genome 10K Project, an international effort to sequence the genome of every species on earth.

Dr. O’Brien emphasized the role of technology and bioinformatics in helping genomics researchers advance human health and species conservation.

“The big questions are difficult,” he said. “But they are solvable with these new technologies.”

Stephen J. O'Brien, Fabia Battistuzzi and Taras Oleksyk

Dr. Stephen O’Brien pictured with symposium organizers Dr. Fabia Battistuzzi and Dr. Taras Oleksyk.

In addition, he cited three elements that universities need to be at the forefront of genomic science:

  • Computer infrastructure and IT support (to meet the computational needs of big data projects)
  • Innovative programmers
  • High-aiming faculty (to train young researchers in the fields of genomics and bioinformatics)

OU President Ora Hirsch Pescovitz introduced Dr. O’Brien and presented him with an OU sweatshirt at the event.

“Dr. O’Brien’s presentation was highly informative, and the type of engaging research work that inspires students and researchers from around the world,” said Dr. Pescovitz. “His talk underscores our goal to be an inspiring environment for research, discoveries and a place that elevates international discourse about significant issues and breakthroughs in science.”

The symposium gathered students and faculty from institutions around the nation to share the latest developments on genomic research. Findings from Cornell University, Penn State University, University of Georgia, University of Michigan, Wayne State University, and Oakland University highlighted the many innovations that genomics is bringing to the fields of conservation biology, medicine, and evolutionary biology, thus impacting every aspect of life

The event also reaffirmed OU’s multi-year commitment to expand research and training in the field of genomics and big data analytics, and provided a unique opportunity for OU students Reagan Miller, Dominic Mier, Justin Kulchycki, Anton Mahama, Ashley Superson, Sarah Medley, Khrystyna Schubelka, and Walter Wolfsberger to showcase their exciting contributions to this growing research endeavor at OU.

In addition, the symposium included an open class in human evolutionary genomics taught by Dr. Juan Rodriguez-Flores, assistant professor of Research in Genetic Medicine, at Weill Cornell Medical College. The symposium was organized by OU Professors Taras Oleksyk and Fabia Battistuzzi, whose teaching and research focus on genomics and evolutionary biology. Sponsorship support was provided by biotech companies Illumina and ThermoFisher Scientific, as well as Sigma Xi, The Scientific Research Honor Society.

Related Posts:

  • No Related Posts

Canopy lays off nearly half of staff

The company received $42 million in funding last May from Tenaya Capital and Nyca Partners, on top of $30 million in earlier funding led by New …

Canopy, a fast-growing practice management and tax software company, laid off over 40 percent of its staff over the weekend.

Before the layoffs, Canopy had been expanding rapidly, and many employees were caught off guard by the sudden layoffs. Canopy has been planning to release a professional tax preparation system, which it began beta testing earlier this year with hopes of launching it in time for next tax season (see Canopy to begin beta testing professional tax prep software). It recently moved into larger headquarters in Levi, Utah, after receiving a grant from the governor’s economic development office and announced plans to double the size of its workforce over the next four years.

Canopy was founded by Kurt Avarell in 2014. He left a career as a Wall Street tax attorney to launch the company, which used to be called Canopy Tax, from his basement. In recent years, the company has rapidly developed a cloud-based practice management system for tax firms, in addition to software for handling tax transcripts. tax notices, and tax resolution management.

“I have personally invested from Day 1 in building a company in which our customers, partners, employees and investors can be proud,” Avarell said in a statement emailed Monday to Accounting Today. “We’re poised for continued growth as we develop solutions to equip the category to tackle key challenges. Unfortunately, this journey now includes the hard decision to part ways with valued team members as we implement the high level of focus and precision needed in the next phase of Canopy’s growth trajectory. I thank each and every team member for their contribution and dedication to the company. Each of these individuals is among the best in their fields, and brought significant vision and strong execution to Canopy during their time here. In fact, as a testament to their talent and to the supportive tech community here in Utah, a free networking breakfast on [March 13] has been set up featuring more than 30 of the region’s top employers to help affected Canopy employees find their next opportunity. Moving ahead, we commit to building on the great foundation put in place by the Canopy team with the support of our investors and partners.”

Founder and CEO of Canopy Kurt Avarell
Founder and CEO of Canopy Kurt Avarell

Canopy is still moving forward with its product development plans, according to spokesperson Andrew Jones: “There will not be any anticipated delay in releasing and enhancing Canopy’s upcoming product offerings.”

In January, when Canopy moved to its new offices, the company touted the advantages of the much larger space. It took over three of the five floors in a newly built corporate space with nearly 80,000 square feet. The building offered employees basketball and pickleball courts, a gym, a library, stocked kitchens, barbecue grills and a smoker, along with maternity/paternity rooms.

Recent social media posts on LinkedIn and Glassdoor suggested that that spending may have contributed to the retrenchment.

“It was very clear that the allocation of money was way out of proportion,” wrote one former employee on Glassdoor. “So many jobs could have been spared had we made better use of the funding we’d been given. It seems that some decisions were extremely rash. Having to lay off 40 percent of the company is not something that should have been decided in two days, but should have been forecasted for months. I gave Canopy my heart and soul and was left with little explanation and absolutely no apology from my managers.”

A current employee was more optimistic about the company’s growth prospects. “It was either layoffs now and focus on fixing core problems and extending the runway long enough to do it or betting all of our jobs on a short-term goal that, if missed, would have meant everyone losing their jobs,” the employee wrote on Glassdoor. “I appreciate the hard decision you made. To those who got let go, my heart goes out. Those of us who stay will do what we can to help you land on your feet. To those who see a big new building and positive press recently, the building and the press was in place before any of this happened. From my understanding the models for why layoffs happened were only fully realized last week. It’s not a reflection of the leadership or the company, but simply the velocity. We were moving too fast and we needed to pump the [brakes]. The future for Canopy is still incredibly bright.”

On LinkedIn, Ted Ferrin, the CEO and co-founder of financial reporting technology company Rivet Software, wrote a post over the weekend encouraging employers to hire the newly laid-off employees. “It’s clear there will be a large recruiting market for Canopy’s talent who is looking for the next job, but nobody knows who is now looking: Please tag anyone as a reply to this particular comment who is looking and fair game,” he wrote. To the company’s current employees, he also encouraged them to stick with it. “To those staying at Canopy, the party isn’t over,” he wrote. “Canopy is in a gigantic market with low/no competition from innovators. Give this 1-2 years of execution and you’ll be back on top.”

Canopy received $42 million in funding last May from Tenaya Capital and Nyca Partners, on top of $30 million in earlier funding led by New Enterprise Associates, along with Wells Fargo Strategic Capital, Pelion Ventures, University Growth Fund and EPIC Venture (see Canopy receives $42M in funding).

Related Posts:

  • No Related Posts